About trastuzumab emtansine
HER2-targeted antibody-drug conjugate
Used for
- HER2-positive early breast cancer after surgery when cancer remains after preoperative treatment
- HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane
Usual adult dose
3.6 mg/kg by intravenous infusion every 3 weeks; treatment duration depends on the indication.
Common side effects
- Fatigue
- Nausea
- Muscle or joint pain
- Low platelet counts
Important warnings
- Can cause liver injury, heart problems, lung inflammation, and severe bleeding.
- May cause nerve damage and low blood counts; regular monitoring is required.
- Harmful to an unborn baby; pregnancy testing and effective contraception are required.
- Do not substitute for trastuzumab; medication errors have caused fatal outcomes.
Pregnancy
Can cause fetal harm. Avoid during pregnancy and for 7 months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment or for 7 months after the last dose.
Interactions
- Strong CYP3A4 inhibitors, such as clarithromycin, may increase exposure; avoid when possible.
- Other medicines that can injure the liver may increase liver-related risks.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.